Skip to main content
    • Aa
    • Aa
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 3
  • Cited by
    This article has been cited by the following publications. This list is generated based on data provided by CrossRef.

    Carroll, Robert J Eyler, Anne E and Denny, Joshua C 2015. Intelligent use and clinical benefits of electronic health records in rheumatoid arthritis. Expert Review of Clinical Immunology, Vol. 11, Issue. 3, p. 329.

    de Smet, Marc D. Taylor, Simon R.J. Bodaghi, Bahram Miserocchi, Elisabetta Murray, Philip I. Pleyer, Uwe Zierhut, Manfred Barisani-Asenbauer, Talin LeHoang, Phuc and Lightman, Sue 2011. Understanding uveitis: The impact of research on visual outcomes. Progress in Retinal and Eye Research, Vol. 30, Issue. 6, p. 452.

    Beresniak, Ariel Medina-Lara, Antonieta Auray, Jean Paul De Wever, Alain Praet, Jean-Claude Tarricone, Rosanna Torbica, Aleksandra Dupont, Danielle Lamure, Michel and Duru, Gerard 2015. Validation of the Underlying Assumptions of the Quality-Adjusted Life-Years Outcome: Results from the ECHOUTCOME European Project. PharmacoEconomics, Vol. 33, Issue. 1, p. 61.

  • International Journal of Technology Assessment in Health Care, Volume 27, Issue 2
  • April 2011, pp. 133-138

Bridging the gap between aggregate data and individual patient management: A Bayesian approach

  • Gert Jan van der Wilt (a1), Hans Groenewoud (a1) and Piet van Riel (a1)
  • DOI:
  • Published online: 08 April 2011

Objectives: The aim of this study was to explore whether Bayesian reasoning can be applied to therapeutic questions in a way that is similar to its application in diagnostics.

Methods: A clinically relevant, therapeutic question was formulated in accordance with Bayesian reasoning for the clinical management of patients with newly diagnosed rheumatoid arthritis (RA). Prior probability estimates of response to drug treatment (methotrexate, MTX) were obtained from the literature. As a marker of treatment response, changes in the Health Assessment Questionnaire (HAQ) scores were assessed after three months of treatment. Likelihood ratios for this marker were calculated on the basis of data from a clinical registry, using changes in the Disease Activity Score (DAS) as gold standard. Using Bayes’ theorem, prior probability and likelihood ratios were combined to estimate posterior probabilities of treatment response in individual patients.

Results: On the basis of the literature, the prior probability of response of RA patients to MTX was estimated 45 percent. At 3 months follow-up, this probability increased to 80 percent or decreased to 23 percent, depending on the changes that were observed in Health Assessment Questionnaire scores.

Conclusions: Bayesian reasoning can be applied to therapeutic issues in a way that is conceptually fully compatible with its use in diagnostics. As such, it can be used to bridge the gap between aggregate data and individual patient management.

Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

1.J Avorn . Debate about funding comparative-effectiveness research. N Engl J Med. 2009;360:19271929.

2.P Barrera , A Van Der Maas , AE van Ede , BA Kiemeney , RF Laan , LB van de Putte , PL van Riel . Drug survival, efficacy and toxicity of monotherapy with a fully human anti-tumour necrosis factor-alpha antibody compared with methotrexate in long-standing rheumatoid arthritis. Rheumatology (Oxford). 2002;41:430439.

5.P Emery , FC Breedveld , S Hall , Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): A randomised, double-blind, parallel treatment trial. Lancet. 2008;372:375382.

7.AM Garber , SR Tunis . Does comparative-effectiveness research threaten personalized medicine? N Engl J Med. 2009;360:19251927.

9. SN Goodman . Toward evidence-based medical statistics. 1: The P value fallacy. Ann Intern Med. 1999;130:9951004.

10.SN Goodman . Introduction to Bayesian methods I: Measuring the strength of evidence. Clin Trials. 2005;2:282290.

11. T Greenhalgh , JG Worrall . From EBM to CSM: The evolution of context-sensitive medicine. J Eval Clin Pract. 1997;3:105108.

12.DA Grimes , KF Schulz . Refining clinical diagnosis with likelihood ratios. Lancet. 2005;365:15001505.

13. H Kuper , A Nicholson , M Kivimaki , Evaluating the causal relevance of diverse risk markers: Horizontal systematic review. BMJ. 2009;339:b4265.

14.AD Naik , LA Petersen . The neglected purpose of comparative-effectiveness research. N Engl J Med. 2009;360:19291931.

15. DL Sackett , WM Rosenberg , JA Gray , Evidence based medicine: What it is and what it isn't. BMJ. 1996;312:7172.

16.H van Dongen , J van Aken , LR Lard , Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: A double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2007;56:14241432.

17. A van Gestel , ML Prevoo , MA van ‘t Hoff , Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum. 1996;39:3440.

18. A van Randen , S Bipat , AH Zwinderman . Acute appendicitis: Meta-analysis of diagnostic performance of CT and graded compression US related to prevalence of disease. Radiology. 2008;249:97106.

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

International Journal of Technology Assessment in Health Care
  • ISSN: 0266-4623
  • EISSN: 1471-6348
  • URL: /core/journals/international-journal-of-technology-assessment-in-health-care
Please enter your name
Please enter a valid email address
Who would you like to send this to? *